## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of	entity
------	----	--------

#### Blackham Resources Limited

ABN

18 119 887 606

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 1. Ordinary shares
- 2. Ordinary shares
- 3. Unlisted options
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 2,000,000
- 2. 75,000
- 3. 175,000
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1 & 2. Fully paid ordinary shares
- 3. Unlisted options exercisable at \$0.91 on or before 3 July 2019.

Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- 1 & 2. Yes rank equally with existing fully paid ordinary shares.
- 3. No upon vesting of options into Ordinary shares, the allotted and issued Ordinary shares will rank equally in all respects with an existing class of quoted securities. The options do not entitle the holder to participate in any dividends or interest payments.

- 5 Issue price or consideration
- 1. Nil
- 2. Nil
- 3. Nil
- 6 Purpose of the issue
  (If issued as consideration for the acquisition of assets, clearly identify those assets)
- 1. Issued under the terms and conditions of the performance rights awarded to executive directors. Performance rights and subsequent issue of shares approved by shareholders on 27/7/15.
- 2. Shares issued under a consulting agreement linked to BLK share price.
- 3. Options for consulting services.
- 6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b The date the security holder resolution under rule 7.1A was passed

27 November 2015 and replenished at GM held on 28 April 2016

6c Number of \*securities issued without security holder approval under rule 7.1

75,000 fully paid ordinary shares

Number of \*securities issued with security holder approval under rule 7.1A

Nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	61,946,403	
7	<sup>+</sup> Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	4 July 2016	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	255,342,103	Fully paid ordinary shares
		Manuels or	+Class
9	Number and +class of all +securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	Number 150,000	*Class \$0.214 Options exercisable on or before 31 July 2016
	z ii appiicavie)	2,500,000	\$0.298 Options exercisable on or before 29 May 2017
		600,000	\$0.298 Options exercisable on or before 1 June 2017

295,000	\$0.25 Options exercisable on or before 24 June 2017
100,000	\$0.30 Options exercisable or or before 24 June 2017
1,000,000	\$0.23 Options exercisable or or before 1 September 2016
1,000,000	\$0.30 Options exercisable on or before 1 September 2017
200,000	\$0.122 Options exercisable on or before 9 November 2016
2,000,000	\$0.500 Options exercisable on or before 14 December 2017
1,000,000	\$0.200 Options exercisable on or before 3 February 2017
1,000,000	\$0.300 Options exercisable on or before 3 February 2018
16,666,667	\$0.180 Options exercisable on or before 31 December 2017
1,770,000	\$0.256 Options (with vesting condition) exercisable on or before 13 October 2017
500,000	\$0.200 Options (with vesting condition) exercisable on or before 13 October 2017
700,000	\$0.256 Performance Options (with vesting conditions) exercisable on or before 31 December 2017
500,000	\$0.256 Options (with vesting condition) exercisable on or before 6 December 2017
500,000	\$0.465 Options exercisable on or before 8 February 2018
175,000	\$0.38 Options exercisable on or before 8 February 2019
175,000	\$0.463 Options exercisable on or before 8 February 2019

	ı		
		3,000,000	\$0.35 Options exercisable on or before 20 March 2018
		5,500,000	Performance Rights (with vesting conditions) on or before 31 December 2017
		500,000	Performance Rights (with vesting conditions) on or before 31 December 2017
		500,000	Performance Rights (with vesting conditions) on or before 31 December 2017
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Bonus issue or pro ra	ıta issue	
	2 201140 10040 01 pro 10		
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates		
15	<sup>+</sup> Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		
18	Names of countries in which the entity has *security holders who will not be sent new issue documents		
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations		

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Despatch date	

### Part 3 - Quotation of securities

34	Type of securities (tick one)
(a)	Securities described in Part 1
(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, emploincentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	es that have ticked box 34(a)
Addit	ional securities forming a new class of securities
Tick to docume	indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of t additional *securities, and the number and percentage of additional *securities held those holders
36	If the *securities are *equity securities, a distribution schedule of the addition *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over
37	A copy of any trust deed for the additional *securities
Entiti	es that have ticked box 34(b)
38	Number of securities for which   †quotation is sought
39	Class of *securities for which quotation is sought
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company Secretary)	 Date: 4 July 2016
Print name:	Mike Robbins	

Appendix 3B Page 9 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	198,383,857	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> <li>Subtract the number of fully paid ordinary</li> </ul>	7,081,578 (option conversions) 665,370 (AGM 27/11/15) 3,500,000 (GM 27/7/15) 45,000,000 (GM 28/4/16)	
securities cancelled during that 12 month period	U .	
"A"	254,630,805	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	38,194,621	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
• Under rule 7.1A	486,298 shares	
With security holder approval under rule	500,000 unlisted options	
7.1 or rule 7.4	500,000 performance rights	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	225,000 shares	
"C"	1,711,298	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	38,194,621	
Note: number must be same as shown in Step 2		
Subtract "C"	1,711,298	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	36,483,323	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 11 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1	254,630,805	
Step 2: Calculate 10% of "A"		
"D"	25,463,080  Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  It may be useful to set out issues of securities on different dates as separate line items  "E"  Step 4: Subtract "E" from ["A" x "E placement capacity under rule 7.1A"	-	
"A" x 0.10  Note: number must be same as shown in Step 2	25,463,080	
Subtract "E"		
Note: number must be same as shown in Step 3	0	
<i>Total</i> ["A" x 0.10] – "E"	25,463,080  Note: this is the remaining placement capacity under rule 7.1A	